Cellect, Inc. Receives Phase II NIH SBIR Grant for potential drug targets breast cancer screen

Mountain View, CA (openPR) 16 September 2010

Cellect, Inc., a contract service provider that specializes in biotechnology, genetic screening to identify new therapeutic targets, has been awarded two years 0.8 million Phase II Small Business Innovation Research (SBIR) to allow to discover and validate potential therapeutic target genes regulate mammary carcinogenesis.

The grant by the National Institutes of Health (NIH funded), will use shRNA libraries Cellect suppressor gene, with funds from the Phase I for the detection of genome-wide identification and development of genes that are necessary for cell growth and viability of the cells in a single set of isogenic human breast gland to maintain epithelial cells (HMEC) are. Repression of genes identified in this screen test viability causes cancer cells to die, and therefore they are good candidates for the development of new classes of anticancer drugs. In cooperation with Peiqing Suna? S Lab at the Scripps Research Institute in La Jolla, California, which are the cell panel HMEC, candidate drug targets developed further validated in mouse models.

? We are very pleased to receive these resources to continue with that study.â?? Cellect said President and CEO Dr. Alex Chenchik. â?? Cellect was created expressly for the purpose of promoting the drug discovery with studies and collaborations such as this, and we look forward to our unique lentiviral shRNA-based pooled libraries for screening applications to pursue large-scale new treatments against cancer. â ????

The current project is part of a series of studies and collaborations Cellectis pinching develop a database of standard reference gene functional activities and therapeutic target molecule-based RNAi library screening.

Cellect, Inc.

Cellect is a private organization, contract research, high-bandwidth (HT) RNAi-based genetic tests for the discovery and functional characterization of new targets accessible. With its unique platform of lentiviral, shRNA, sequencing, HT, and bioinformatics technologies, they deliver the shRNA library screening and sequencing pooled lentiviral shRNA libraries and HT reporter dismantled stable overexpression or cell lines. Scientists Cellectaâ? have developed some of the most modern technologies, developed in collaboration with opinion leaders and with funding from eleven NIH SBIR grants. For more information, visit the Web site Cellect.

Scripps Research Institute, one of the nation’s largest, has private research institutions, non-profit, always at the forefront of basic biomedical science, an important area of medical research aims to understand the fundamental processes of life. In three decades the Institute has established a long roadmap of major contributions to improving the health and human existence. The Institute has an international reputation for basic research in immunology, molecular and cellular biology, chemistry, neurosciences, autoimmune diseases, heart cardiovascular disease, virology and synthetic vaccine development won. Of particular importance is the Institute study the fundamental structure and design of biological molecules, belongs in this area TSRI to a handful of the most important centers of the world.

###

clear = “all”
Drugs for breast cancer